Somewhat Positive News Coverage Somewhat Unlikely to Impact Meridian Bioscience (VIVO) Share Price

Media coverage about Meridian Bioscience (NASDAQ:VIVO) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Meridian Bioscience earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 48.433000830088 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Several equities research analysts have recently issued reports on the company. BidaskClub raised Meridian Bioscience from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 19th. TheStreet raised Meridian Bioscience from a “c+” rating to a “b” rating in a report on Monday, July 2nd. Finally, Zacks Investment Research upgraded Meridian Bioscience from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Tuesday, May 1st.

VIVO traded down $0.03 on Wednesday, hitting $14.90. The company had a trading volume of 9,004 shares, compared to its average volume of 243,212. The firm has a market cap of $635.93 million, a P/E ratio of 22.24 and a beta of 0.85. Meridian Bioscience has a 12-month low of $13.50 and a 12-month high of $17.10. The company has a current ratio of 5.73, a quick ratio of 3.89 and a debt-to-equity ratio of 0.27.



Meridian Bioscience (NASDAQ:VIVO) last released its quarterly earnings results on Tuesday, July 31st. The company reported $0.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.17 by $0.01. The company had revenue of $51.74 million during the quarter, compared to analyst estimates of $52.17 million. Meridian Bioscience had a return on equity of 16.97% and a net margin of 11.49%. The firm’s revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the business posted $0.16 earnings per share. research analysts forecast that Meridian Bioscience will post 0.7 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, August 20th. Investors of record on Friday, August 10th will be given a $0.125 dividend. The ex-dividend date of this dividend is Thursday, August 9th. This represents a $0.50 annualized dividend and a yield of 3.36%. Meridian Bioscience’s dividend payout ratio is currently 74.63%.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Further Reading: Diversification in Your Portfolio

Insider Buying and Selling by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply